Modified Rankin Scale

New Data Links Modulation of Key Immune-Related Proteins to Improvement of Specific Symptoms in Long COVID

Retrieved on: 
Thursday, February 16, 2023
COVID-19, Research, Infectious Diseases, Biotechnology, Other Health, Health, General Health, Other Science, Science, Biomarker, PASC, Fatigue, NYHA, Trial of the century, Randomized controlled trial, Frontiers in Medicine, Diagnosis, Patient, MRC, Timeline of the COVID-19 pandemic in the United Kingdom, FSS, Medical Research Council (United Kingdom), New York Heart Association Functional Classification, Georgetown University School of Nursing, Medical Research Council, COMPASS, CDC, Survivor, Modified Rankin Scale, DSM-IV codes, Chronic, ME/CFS, Pravastatin, Clinical descriptions of chronic fatigue syndrome, Community, Alternative medicine, Classification, Pharmaceutical industry, Medical imaging, Maraviroc, COVID, Medicine

Data from a new clinical study show modulation of key immune regulating proteins with maraviroc and pravastatin correlates with symptom reduction in patients with post-acute sequelae of COVID (PASC), commonly known as long COVID.

Key Points: 
  • Data from a new clinical study show modulation of key immune regulating proteins with maraviroc and pravastatin correlates with symptom reduction in patients with post-acute sequelae of COVID (PASC), commonly known as long COVID.
  • The study results, published in Frontiers in Medicine, also support a precision medicine approach to diagnosis of long COVID as well as differentiation of long COVID from ME-CFS (myalgic encephalomyelitis/chronic fatigue syndrome), which presents with similar symptoms.
  • Subjective neurological, autonomic, respiratory, cardiac and fatigue symptoms scores all decreased by statistically significant margins.
  • In particular, the FSS (fatigue being the most common symptom) decreased and was closely correlated in decreases of IL-2 and TNF-α.

Update on Acticor Biotech's clinical developments with glenzocimab in the treatment of cardiovascular emergencies

Retrieved on: 
Monday, January 9, 2023
Biotechnology, Pharmaceutical, Health, Cardiology, University, Hospital, IRB, Alteplase, AP, Type, University Hospitals Birmingham NHS Foundation Trust, Agence nationale de sécurité du médicament et des produits de santé, Partnership, Marketing, Assistance Publique–Hôpitaux de Paris, Stroke, Infarction, ISIN, RHU, Biologics license application, European Medicines Agency, Death, Quality of life, Pulmonary embolism, BLA, EVT, Sri Jayadeva Institute of Cardiovascular Sciences and Research, TNK, EMA, Agence nationale de la recherche, FDA, MRS, Disability, Tenecteplase, IRAS, Șaeș, Reperfusion, Standard of care, Safety, IPO, Modified Rankin Scale, Patient, Thrombectomy, Myocardial infarction, GREEN, Pharmaceutical industry, Medical imaging

ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.

Key Points: 
  • ACTICOR BIOTECH (ISIN: FR0014005OJ5 - ALACT), a clinical-stage biotechnology company focused on the development of innovative drugs for the treatment of cardiovascular emergencies, in particular stroke, today provides an update on the progress of its clinical programs with glenzocimab, its lead drug candidate.
  • We have fully met our patient enrollment goals in 2022 and are involving new countries and hospitals in 2023.
  • We look forward to continuing the clinical development of glenzocimab in the treatment of myocardial infarction in partnership with the University of Birmingham (UK).
  • The recognition of this pivotal study design supports a future application for marketing authorization for glenzocimab in stroke in Europe.

Corindus, A Siemens Healthineers Company, Announces Study Results Demonstrating Safety and Effectiveness of CorPath® GRX Neurovascular System

Retrieved on: 
Monday, September 12, 2022
Robotics, Medical Devices, Health, Technology, Surgery, Health Technology, Workflow, Safety, Aneurysm, Modified Rankin Scale, FDA, European Society of Cardiology, CE marking, Thrombosis, Patient, Physician, Dissection, Â, MRS, Doctor of Philosophy, Robotics, Collection, Congress, Multimedia, AI, Pharmaceutical industry, Medical device, Corindus Vascular Robotics, MD

Corindus , A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System.

Key Points: 
  • Corindus , A Siemens Healthineers Company and a leading developer of precision vascular robotics, announced today it presented the results of a first-of-its-kind study demonstrating the safety and effectiveness of robotic-assisted neurovascular aneurysm embolization using the CorPath GRX Neurovascular System.
  • View the full release here: https://www.businesswire.com/news/home/20220907006221/en/
    CorPath GRX Neurovascular System (Photo: Business Wire)
    The prospective, single-arm, international, multi-center, non-inferiority study is the worlds first trial on robotic-assisted neurovascular aneurysm embolization.
  • Key findings of the study showed:
    The CorPath GRX Neurovascular System demonstrated 94 percent technical success.
  • The results of the study show the CorPath GRX System helps physicians move efficiently within tortuous and unstable vessels.

Community Health Systems to Present Encouraging Results of Safety Program Employing PeriGen's Vigilance Early Warning System at IHI Patient Safety Congress 2022

Retrieved on: 
Friday, May 13, 2022
Company, Modified Rankin Scale, Patient safety, Perigenes, CHS, Leadership, Patient, Health, Community Health Systems, Health care, Obstetrics, Birth injury, Contribution, YouTube, Hospital, Communication, CYH, Heart, LinkedIn, Twitter, Bed, CEO, Medicine, Vigilance, Facebook

CARY, N.C., May 13, 2022 /PRNewswire/ -- PeriGen Inc., the market leader in automated maternal-fetal early warning systems, today announced that Community Health Systems (CHS), a leading operator of general acute care hospitals in communities across the country, will present results realized after its implementation of PeriGen's PeriWatch Vigilance early warning and clinical decision support system at the IHI Patient Safety Congress 2022 (May 16-18 in Dallas, plus virtual). Vigilance is at the heart of the monitoring and communication program designed to reduce adverse events in childbirth.

Key Points: 
  • Vigilance is at the heart of the monitoring and communication program designed to reduce adverse events in childbirth.
  • The initial results achieved by the CHS hospital labor and delivery departments using PeriWatch Vigilance will be shared via poster session.
  • The results, titled "Reducing Modifiable Factors that Contribute to Preventable Birth Injury," highlights the patient safety improvement program's early data following the implementation of Vigilance as part of an obstetrics safety initiative.
  • "CHS leadership made Vigilance adoption a priority system wide and is now realizing the benefits of this commitment.

BrainQ announces encouraging study results for new therapy to reduce disability after stroke

Retrieved on: 
Thursday, March 11, 2021
Rehabilitation medicine, Medicine, Clinical medicine, Stroke, Health, Modified Rankin Scale

After 8 weeks of treatment, 77% of the subjects receiving the BrainQ therapy had scores of 1 or 0 on the modified Rankin Scale (mRS), the gold standard for measuring disability following stroke.

Key Points: 
  • After 8 weeks of treatment, 77% of the subjects receiving the BrainQ therapy had scores of 1 or 0 on the modified Rankin Scale (mRS), the gold standard for measuring disability following stroke.
  • This translates to subjects having either no symptoms or minor symptoms, and with no significant disability.
  • "With 800,000 strokes each year in the US alone, this therapy has the potential to greatly advance stroke care.
  • Israel-based start-up BrainQ is developing an AI-powered therapeutic platform for reducing disability following stroke and other neurodisorders, with the goal of transforming the lives of millions.